ScholarIQanswers from OpenAlex & ORCID
Gerd‐Rüdiger Burmester
ResearcherPublications, citations & collaboration network
Gerd‐Rüdiger Burmester is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Gerd‐Rüdiger Burmester have?
ScholarIQindexed works
Gerd‐Rüdiger Burmester has 240 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Gerd‐Rüdiger Burmester have?
ScholarIQcitation count
Gerd‐Rüdiger Burmester has 17,477 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Gerd‐Rüdiger Burmester?
ScholarIQh-index
Gerd‐Rüdiger Burmester has an h-index of 53 in OpenAlex.
What is the i10-index of Gerd‐Rüdiger Burmester?
ScholarIQi10-index
Gerd‐Rüdiger Burmester has an i10-index of 132 in OpenAlex.
What is the OpenAlex record for Gerd‐Rüdiger Burmester?
ScholarIQopenalex
The OpenAlex for Gerd‐Rüdiger Burmester is on the source record.
What are the most-cited papers on Gerd‐Rüdiger Burmester?
ScholarIQmost cited works
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
D. Aletaha, Tuhina Neogi, Alan J. Silman, Julia Funovits, David T. Felson, Clifton O. Bingham, Neal S Birnbaum, Gerd‐Rüdiger Burmester, V. P. Bykerk, Marc D. Cohen, B. Combe, Karen H. Costenbader, M. Dougados, P. Emery, Gianfranco Ferraccioli, Johanna M. W. Hazes, Kathryn Hobbs, T. Huizinga, A. Kavanaugh, Jonathan Kay, T.K. Kvien, Timothy Laing, Philip J. Mease, Henri A Ménard, Larry W. Moreland, Raymond L. Naden, Theodore Pincus, Josef S Smolen, E. Stanislawska-Biernat, Deborah Symmons, P. P. Tak, Katherine S. Upchurch, Jiří Vencovský, Fred Wolfe, Gillian Hawker
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska